Investigational drug · Phase 3
KITE-753
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Relapsed or Refractory Large B-cell Lymphoma, Relapsed and/or Refractory B-cell Lymphoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "KITE-753"
First trial start
2021
Oct 27, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KITE-753", any sponsor or status.
Conditions studied
As listed on its trial records.
- Relapsed or Refractory Large B-cell Lymphoma
- Relapsed and/or Refractory B-cell Lymphoma
Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "KITE-753" as an intervention, largest first.
- Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite StudiesEnrolling by invitation
Kite, A Gilead CompanyGilead Sciences (GILD)
NCT05041309 · 1,500 participants (planned) · Start Dec 15, 2021 · Primary completion Dec 2040
Drug: Axicabtagene Ciloleucel; Brexucabtagene Autoleucel and 9 more · For: Solid and Hematological Malignancies; Autoimmune Diseases
Sites: Gilbert, Arizona; Duarte, California; La Jolla, California · 91 sites in all
- Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line TherapyPivotal-lookingActive, not recruiting
Kite, A Gilead CompanyGilead Sciences (GILD)
NCT07479797 · 550 participants (planned) · Start May 22, 2026 · Primary completion May 2031
Drug: KITE-753; Axicabtagene Ciloleucel and 2 more · For: Relapsed or Refractory Large B-cell Lymphoma
Sites: Goodyear, Arizona; Duarte, California; Stanford, California · 42 sites in all
- Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell LymphomaActive, not recruiting
Kite, A Gilead CompanyGilead Sciences (GILD)
NCT04989803 · 247 participants (planned) · Start Oct 27, 2021 · Primary completion Feb 2030
Drug: Cyclophosphamide; Fludarabine and 2 more · For: Relapsed and/or Refractory B-cell Lymphoma
Sites: Gilbert, Arizona; Duarte, California; Stanford, California · 36 sites in all
- Study Of KITE-753 in R/R B-Cell ALLNot yet recruiting
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT07674823 · 18 participants (planned) · Start Dec 31, 2026 · Primary completion Apr 1, 2029
Drug: KITE-753 · For: B-cell Acute Lymphoblastic Leukemia
Sites: Houston, Texas
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Gilead Sciences.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.